缺血性心脏病的常规治疗虽然可以改善冠状动脉供血、挽救缺血心肌,但无法使已坏死的心肌再生,所以应用干细胞替代受损及死亡的心肌细胞改善心功能逐渐成为近年来国内外研究的焦点。骨髓间充质干细胞具有取材方便、容易体外培养和扩增、基因转染效率高可取自于自身,实现自体移植,避免了免疫排斥反应,且不存在伦理学的制约,有望成为治疗缺血性心脏病的理想细胞来源。 Although the conventional treatment of ischemic heart disease can improve coronary blood supply, save the ischemic myocardium, but can not be necrosis of the myocardium regeneration, so the application of stem cells to replace damaged and dead cardiomyocytes to improve cardiac function has gradually become the research in recent years Focus. Bone marrow mesenchymal stem cells are easy to obtain, easy to be cultured and expanded in vitro, high transfection efficiency can be taken from themselves, to achieve autologous transplantation, to avoid immune rejection, and there is no ethical constraints, is expected to become the treatment of ischemia The ideal source of a heart disease.